Summit Creek Advisors LLC Sells 36,560 Shares of Bio-Techne Corp $TECH

Posted by Francis Steltz on Nov 8th, 2026

Summit Creek Advisors LLC trimmed its stake in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 28.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 93,064 shares of the biotechnology company’s stock after selling 36,560 shares during the period. Bio-Techne accounts for 2.7% of Summit Creek Advisors LLC’s portfolio, making the stock its 7th largest holding. Summit Creek Advisors LLC’s holdings in Bio-Techne were worth $6,744,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. S&CO Inc. bought a new position in Bio-Techne during the second quarter valued at $5,412,000. HBK Investments L P purchased a new position in shares of Bio-Techne in the 2nd quarter worth $482,186,000. American Capital Management Inc. increased its holdings in shares of Bio-Techne by 8.5% in the 1st quarter. American Capital Management Inc. now owns 1,021,128 shares of the biotechnology company’s stock worth $53,364,000 after buying an additional 79,979 shares during the last quarter. Maven Securities LTD bought a new stake in shares of Bio-Techne in the 2nd quarter worth about $3,865,000. Finally, Squarepoint Ops LLC raised its position in shares of Bio-Techne by 2,094.5% during the 2nd quarter. Squarepoint Ops LLC now owns 91,268 shares of the biotechnology company’s stock valued at $6,448,000 after buying an additional 87,109 shares in the last quarter. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Stock Up 0.2%

NASDAQ TECH opened at $72.78 on Friday. The company has a quick ratio of 3.35, a current ratio of 4.55 and a debt-to-equity ratio of 0.09. Bio-Techne Corp has a 52 week low of $43.19 and a 52 week high of $72.83. The firm has a market capitalization of $11.43 billion, a price-to-earnings ratio of 63.29, a PEG ratio of 5.28 and a beta of 1.29. The company has a fifty day moving average of $72.48 and a two-hundred day moving average of $63.38.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.44 earnings per share for the quarter, meeting the consensus estimate of $0.44. Bio-Techne had a net margin of 14.97% and a return on equity of 13.23%. The business had revenue of $299.71 million for the quarter, compared to the consensus estimate of $292.60 million. On average, analysts predict that Bio-Techne Corp will post 1.75 earnings per share for the current year.

Bio-Techne Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 23rd. Investors of record on Friday, November 13th will be paid a dividend of $0.08 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.4%. This is a drop from Bio-Techne’s previous quarterly dividend of $0.65. Bio-Techne’s dividend payout ratio is presently 27.83%.

Analysts Set New Price Targets

A number of research analysts recently commented on TECH shares. Wells Fargo & Company downgraded shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $62.00 to $73.00 in a report on Thursday, August 13th. Benchmark reissued a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Zacks Research raised Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Argus downgraded Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research report on Monday, October 26th. Finally, Weiss Ratings raised Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bio-Techne presently has an average rating of “Hold” and an average price target of $68.92.

Get Our Latest Report on Bio-Techne